SAB Biotherapeutics, Inc. (SABS)

4.1000 -0.1800 (-4.21%) At close: 04:00PM EDT

SAB Biotherapeutics, Inc.

2100 East 54th Street North
Sioux Falls, SD 57104
United States
605 679 6980
https://www.sabbiotherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 57

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Samuel J. Reich	CEO & Executive Chairman	363.2k	N/A	1975
Dr. Eddie Joe Sullivan Ph.D.	Co-Founder, President & Director	402.56k	N/A	1967
Ms. Christine E. Hamilton M.B.A.	Co-Founder & Independent Director	25k	N/A	1956
Mr. Michael George King Jr.	EVP & CFO	60.58k	N/A	1961
Dr. Christoph Bausch M.B.A., Ph.D.	Executive VP & COO	443.2k	N/A	1971
Dr. Alexandra Kropotova M.B.A., M.D.	Executive VP & Chief Medical Officer	774.45k	N/A	1973
Dr. Edward D. Hamilton D.V.M.	Co-Founder & Board Observer	N/A	N/A	N/A
Dr. Carlos N. Carillo Ph.D.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

Corporate governance

SAB Biotherapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.